Search research articles
Contact Us
Filters
Showing results (201-210 of 321) with videos related to
Page
of 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2016
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline
Erik P Sulman, Nofisat Ismaila, Terri S Armstrong, et al.
Neuro-Oncology
|
July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients
Kourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Neuro-Oncology
|
November 4, 2017
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype
Jian Teng, Seyedali Hejazi, Lotte Hiddingh, et al.
Journal of Neuro-Oncology
|
July 24, 2012
Prospective, high-throughput molecular profiling of human gliomas
Andrew S Chi, Tracy T Batchelor, Dora Dias-Santagata, et al.
Cancer Research
|
June 25, 2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
A Gregory Sorensen, Tracy T Batchelor, Wei-Ting Zhang, et al.
German Medical Science : GMS E-Journal
|
June 24, 2011
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis
Katrin Patrij, Marcel Reiser, Luise Wätzel, et al.
Cancer Research
|
June 20, 2017
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated Cytotoxicity
Kensuke Tateishi, Fumi Higuchi, Julie J Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
Ovidiu C Andronesi, Franziska Loebel, Wolfgang Bogner, et al.
Neuro-Oncology
|
May 27, 2015
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Elizabeth R Gerstner, Xiaobu Ye, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
Daniel P Cahill, Kymberly K Levine, Rebecca A Betensky, et al.
Page
of 33
Search research articles
Search
Showing results (201-210 of 321) with videos related to
Sort By:
Page
of 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2016
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline
Erik P Sulman, Nofisat Ismaila, Terri S Armstrong, et al.
Neuro-Oncology
|
July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients
Kourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Neuro-Oncology
|
November 4, 2017
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype
Jian Teng, Seyedali Hejazi, Lotte Hiddingh, et al.
Journal of Neuro-Oncology
|
July 24, 2012
Prospective, high-throughput molecular profiling of human gliomas
Andrew S Chi, Tracy T Batchelor, Dora Dias-Santagata, et al.
Cancer Research
|
June 25, 2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
A Gregory Sorensen, Tracy T Batchelor, Wei-Ting Zhang, et al.
German Medical Science : GMS E-Journal
|
June 24, 2011
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis
Katrin Patrij, Marcel Reiser, Luise Wätzel, et al.
Cancer Research
|
June 20, 2017
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated Cytotoxicity
Kensuke Tateishi, Fumi Higuchi, Julie J Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
Ovidiu C Andronesi, Franziska Loebel, Wolfgang Bogner, et al.
Neuro-Oncology
|
May 27, 2015
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Elizabeth R Gerstner, Xiaobu Ye, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
Daniel P Cahill, Kymberly K Levine, Rebecca A Betensky, et al.
Page
of 33